SleepZee Anti-Snoring Mouthpiece Consumer Report: 2026 Analysis of Mandibular Advancement Device Research, Snoring Reduction Claims, and What Buyers Should Verify




SleepZee Anti-Snoring Mouthpiece Consumer Report: 2026 Analysis of Mandibular Advancement Device Research, Snoring Reduction Claims, and What Buyers Should Verify

A 2026 informational consumer research report examining SleepZee anti-snoring mouthpiece mandibular advancement claims, boil-and-bite snoring mouth guard effectiveness research, company Terms of Service disclosures, refund policy analysis, and what consumers should verify before purchasing

Pittsburgh, PA, March 06, 2026 (GLOBE NEWSWIRE) — This article contains affiliate links. If a purchase is made through these links, a commission may be earned at no additional cost to the buyer. This article is an informational overview and does not constitute medical advice. All product details described below are stated as presented by the company and should be verified directly on the official website before any purchasing decision. Consult qualified healthcare professionals before using any anti-snoring product.

Consumers researching anti-snoring mouthpieces online have likely encountered SleepZee, a boil-and-bite mandibular advancement device marketed as a solution for nighttime snoring. With growing interest in stop-snoring mouthpiece options that do not require a prescription or clinical fitting, products like SleepZee have gained visibility across social media, product review sites, and wellness blogs.

This report reviews how the product is described by the company, how mandibular advancement devices function according to published research, and what consumers may wish to verify before purchasing. Current product details and pricing can be confirmed by view the current SleepZee product information (official SleepZee page).

Individual results vary. Persistent snoring or suspected sleep apnea should be evaluated by a qualified healthcare provider before relying on any over-the-counter device.

Growing Consumer Interest in Anti-Snoring Mouthpieces

Snoring affects a significant portion of the adult population. Published estimates suggest that habitual snoring occurs in roughly 40% of adult men and 24% of adult women, with prevalence increasing with age and body weight. Beyond the person who snores, research has shown that partners of habitual snorers frequently lose meaningful sleep, which can affect daytime energy, mood, and relationship quality over time.

That context helps explain why consumer searches for terms like “anti snoring mouthpiece,” “stop snoring mouth guard,” and “mandibular advancement device for snoring” have grown steadily. People are looking for affordable, non-invasive alternatives to CPAP machines and expensive dental appliances, and boil-and-bite snoring mouth guards sit at the accessible end of that spectrum.

SleepZee is one of the products appearing in those searches. This report examines how the company describes the product, what the published research on mandibular advancement devices actually supports, and where consumers may want to dig deeper before placing an order.

What Is SleepZee and How the Company Describes It

According to the company’s published Terms of Service, SleepZee is a brand name operated by UAB CommerceCore, a limited liability company registered in Lithuania. The Terms also state that products are delivered from fulfillment centers in China. A separate storefront at thesleepzee.com lists a U.S. mailing address in Pittsburgh, Pennsylvania.

According to the company, SleepZee works by repositioning the lower jaw forward during sleep to help maintain airflow and reduce the soft tissue vibration that causes snoring. The website describes the product as made from medical-grade silicone that is non-toxic and BPA-free. The company markets the mouthpiece as adjustable, comfortable, and effective for snoring reduction.

One storefront (sleepzee.com) displays a 4.7 average rating based on what it describes as 8,256 customer reviews. A separate storefront (thesleepzee.com) references over 1.5 million satisfied customers and presents specific outcome statistics, including that 95% of users reported uninterrupted sleep, 90% improved their relationships, and 81% saw a reduction in high blood pressure. These statistics are presented without citation to a published study or disclosed methodology.

The company’s own Terms of Service include this statement: “Our Products are not medical devices and are not intended to diagnose, treat, cure, or prevent any disease or condition.” That disclosure is worth keeping in mind alongside health-related outcome claims presented elsewhere on the product pages.

Mandibular Advancement Devices: What Published Research Shows

The mechanism behind SleepZee — mandibular advancement — is well established in sleep medicine. When the lower jaw moves forward during sleep, it pulls the tongue and surrounding soft tissues away from the back of the throat, which can reduce airway obstruction and the vibration that produces snoring sounds.

Published peer-reviewed research supports this approach. A Cochrane systematic review examined multiple randomized controlled trials and concluded that oral appliances, including mandibular advancement devices, were effective at reducing snoring frequency and intensity compared to no treatment. The American Academy of Sleep Medicine has published clinical practice guidelines recognizing custom-fitted oral appliances as a treatment option for primary snoring and mild to moderate obstructive sleep apnea.

Oral appliance therapy for snoring has been widely discussed in sleep medicine literature, particularly for patients seeking alternatives to continuous positive airway pressure devices or surgical interventions.

Here is the distinction that matters: the research supporting mandibular advancement devices was conducted primarily on custom-fitted devices made by dental professionals, where the degree of jaw advancement is precisely calibrated. Those devices typically cost hundreds to thousands of dollars and involve clinical oversight. The published evidence supporting professional-grade MADs does not automatically extend to every over-the-counter boil-and-bite anti-snoring mouthpiece in the same category.

That does not mean boil-and-bite devices cannot work for some people. It means that if you are comparing a specific product to published clinical research, the device type and fitting method matter.

How the Product Is Marketed and What Consumers May Wish to Verify

Consumers searching for terms such as “SleepZee review,” “does SleepZee work,” or “SleepZee medically proven” often encounter marketing language describing the product as clinically supported, doctor-designed, and backed by research. Here is what is worth verifying.

“Backed by decades of research and clinical trials” likely references the broader body of published research on mandibular advancement as a mechanism, which does span several decades. No published clinical trial evaluating SleepZee as a specific product appears in major medical databases including PubMed as of this writing.

“Designed and recommended by sleep doctors” is supported on the website by a single named endorsement attributed to “Dr. Emily Sato, Director of the Pacific Sleep Health Center.” However, the company’s Terms of Service disclose that “testimonials and/or comments displayed on the Website might have fictional names and associative pictures.” Consumers may wish to independently verify professional credentials referenced on product websites.

The health outcome statistics (95% uninterrupted sleep, 81% reduced blood pressure) are presented without source citations. Blood pressure reduction in particular is a medical outcome that typically requires controlled measurement to substantiate, which creates a tension with the company’s own statement that the product is not a medical device.

SleepZee Pricing and Purchase Structure

The sleepzee.com website advertises a 70% discount with a countdown timer. The thesleepzee.com storefront lists a single mouthpiece at approximately $35.75, reduced from a stated original price of $79.99, with a multi-unit bundle also available. According to the company, all orders include free worldwide shipping. Products ship from China per the published Terms of Service.

Pricing and promotional terms may change. Verify current details by view the current SleepZee product information (official SleepZee page) before ordering.

SleepZee Refund Policy: What the Terms Actually Say

This is an area worth reading carefully, because the marketing language and the published legal terms describe the refund process differently.

The product pages advertise a 30-night money-back guarantee and reference 100% satisfaction. However, the published Terms of Service on sleepzee.com define refund eligibility more specifically. According to the Terms, eligible reasons for a return or refund are: (1) the product is damaged upon delivery, or (2) the order is canceled within 12 hours of purchase.

The Terms also state: “By agreeing to these Terms, you confirm that you understand that the purchased Products may not be returned once they are delivered to you and you have opened the Product package.”

The Terms of Service describe specific conditions for refunds that may differ from how the guarantee is summarized on product pages. Because an anti-snoring mouthpiece must be opened to be used, consumers should review the complete Terms of Service and confirm refund terms in writing with the company before ordering.

Who This Device May Be Suitable For

SleepZee may align with consumers who are: exploring affordable, over-the-counter snoring solutions as a starting point; comfortable wearing an in-mouth device during sleep; experiencing mild snoring primarily caused by jaw and tongue positioning; or looking for a portable, travel-friendly option.

Other options may be preferable for consumers who: have moderate to severe obstructive sleep apnea requiring clinical management; need precise jaw advancement calibrated by a dental professional; have TMJ disorders, dental conditions, or wear dentures; or prefer a product with independently published clinical trial data.

Consumers researching over-the-counter snoring devices often consider whether their snoring has been medically evaluated, whether refund policies are clearly understood before ordering, and whether the underlying cause of their snoring has been identified. These are practical questions worth answering before committing to any anti-snoring mouthpiece purchase.

Consumer Verification Checklist

Verify the source of published statistics. When a website presents specific outcome percentages, look for the underlying study and methodology. If that information is not available, contact the company directly.

Separate category research from product evidence. Mandibular advancement is well supported as a mechanism. That does not mean every product using that mechanism has been independently tested.

Read the Terms of Service before ordering. Compare the advertised guarantee with the published refund conditions. Ask for written confirmation of what qualifies for a return.

Consult a healthcare provider. This step is especially important for persistent snoring, suspected sleep apnea, or existing jaw and dental conditions.

Consumers researching anti-snoring mouthpieces frequently search phrases such as “SleepZee review,” “does SleepZee work,” or “SleepZee anti-snoring mouthpiece effectiveness.” These queries reflect common consumer research behavior when evaluating over-the-counter snoring devices. Understanding how the product is described by the company and how mandibular advancement devices function more broadly may help consumers interpret those search results more effectively.

Consumer Questions About SleepZee

Is SleepZee FDA approved? The website does not display documentation indicating FDA clearance. Consumers interested in regulatory classification may consult the FDA medical device database or contact the company directly for clarification. The company’s own Terms of Service state the product is not a medical device.

What is mandibular advancement and is it proven? Mandibular advancement refers to the forward repositioning of the lower jaw during sleep. Published research and AASM guidelines support this mechanism for reducing snoring. The effectiveness of any specific over-the-counter product depends on fit quality, degree of advancement, and individual anatomy.

How long does SleepZee last? According to the thesleepzee.com website, the mouthpiece can last up to six months with proper care. Actual lifespan depends on how often it is used and individual bite force.

Can SleepZee help with sleep apnea? The thesleepzee.com website states the product can “alleviate obstructive sleep apnea symptoms.” Sleep apnea is a medical condition that requires professional evaluation. Over-the-counter devices are not a substitute for CPAP therapy or professionally fitted oral appliances. The sleepzee.com Terms of Service state the product is not intended to treat any disease or condition.

Are the testimonials on the website verified? The company’s Terms of Service disclose that testimonials may use fictional names and associative pictures. The identity of consumers is described as known to the company but not necessarily displayed.

Who operates SleepZee? According to the published Terms of Service, SleepZee is operated by UAB CommerceCore, registered in Lithuania. Products ship from China. Customer support is available at support@sleepzee.com and by phone at +1 (659) 274-5680.

Additional Consumer Research

Consumers researching SleepZee may benefit from reviewing previously published reporting. A 2026 consumer analysis examining SleepZee company transparency and device claims provides additional context on the company’s background. A separate anti-snoring mouthpiece vs. nose strips format comparison covers how consumers evaluate different anti-snoring product categories.

Evaluating multiple sources is recommended before making any purchasing decision. Consumers may also wish to review the American Academy of Sleep Medicine’s published guidelines on oral appliance therapy.

Summary of Key Considerations

SleepZee is a boil-and-bite mandibular advancement mouthpiece marketed for snoring reduction. While published research supports the mechanism behind this category of device, publicly available clinical trials evaluating SleepZee specifically were not identified at the time of writing. Several marketing claims on the website, including health outcome statistics and medical endorsements, are presented without publicly accessible source documentation. The company’s own Terms of Service state the product is not a medical device and disclose that testimonials may use fictional names.

The advertised 30-night money-back guarantee is described differently in the published Terms of Service. Consumers should review the complete Terms and confirm refund eligibility in writing before ordering.

Complete product details, current pricing, and published terms are available by view the current SleepZee product information (official SleepZee page).

Contact Information

According to the company’s official websites, SleepZee provides customer support through the following channels:

Email: support@sleepzee.com

Phone: +1 (659) 274-5680

Live Chat: According to the website, 24/7 live chat is available on sleepzee.com

Company: UAB CommerceCore, Savanorių pr. 363, Kaunas, Lithuania

U.S. Address (per thesleepzee.com): 322 North Shore Drive, Pittsburgh, PA 15212, USA

Website: sleepzee.com

Disclaimers

Content and Medical Disclaimer: This article is an independent informational overview and does not constitute medical, health, or diagnostic advice. All product details, material claims, pricing, and policy terms described in this article are stated as presented by the company on its publicly available website and product pages. Snoring can be a symptom of obstructive sleep apnea or other medical conditions. Readers are encouraged to consult a qualified healthcare professional before using any anti-snoring product, particularly individuals with existing health conditions, jaw disorders, dental concerns, or suspected sleep apnea.

Anti-Snoring Device Notice: The company’s own Terms of Service state that SleepZee products “are not medical devices and are not intended to diagnose, treat, cure, or prevent any disease or condition.” The effectiveness of mandibular advancement devices varies based on individual anatomy, the underlying cause of snoring, device fit quality, and consistency of use. Published research supporting mandibular advancement was conducted primarily on professionally fitted devices and does not automatically extend to all over-the-counter products in this category.

Results, Pricing, and Product Variability: All pricing, promotional offers, shipping terms, and refund policies referenced in this article are based on information published on the official product websites at the time of writing (March 2026) and may change without notice. Statistics presented on the company’s website are company-reported figures; the underlying methodology has not been independently verified by the publisher of this article.

FTC Affiliate Disclosure and Publisher Responsibility: This article contains affiliate links. If a product is purchased through these links, a commission may be earned at no additional cost to the buyer. This compensation does not influence the accuracy, neutrality, or integrity of the information presented. The publisher of this article is not responsible for typographical errors, manufacturer changes after publication, or individual consumer outcomes.

CONTACT: Email: support@sleepzee.com
Phone: +1 (659) 274-5680

Holland Bloorview Kids Rehabilitation Hospital launches its 10th annual Capes for Kids fundraiser




Holland Bloorview Kids Rehabilitation Hospital launches its 10th annual Capes for Kids fundraiser

Calling all fundraisers to don their capes from March 6-13 to support children with disabilities

Toronto, March 06, 2026 (GLOBE NEWSWIRE) — Holland Bloorview Kids Rehabilitation Hospital (Holland Bloorview) kicks off its 10th annual Capes for Kids fundraising campaign, presented by BMO, to support kids and youth with disabilities and developmental differences and their families. From March 6-13, 2026, the hospital is daring as many new, and returning, fundraisers as possible to show up, get loud and join Holland Bloorview’s mission. By donning superhero capes throughout the week supporters can also help spark important conversations about disability inclusion. Since 2017, the campaign has raised nearly $8 million for the most urgent care and research needs at Holland Bloorview.

“As Canada’s hospital for children with disabilities, we are forging a bold and daring path forward to shape the future of disability health care. This means expanding access, driving excellence in lab-to-clinic innovations and accelerating disability inclusion and health equity,” said Sandra Hawken, president and CEO, Holland Bloorview Foundation. “We simply couldn’t do this work without the legions of  dedicated fundraisers—including donors and sponsors—who rally on behalf of thousands of clients and families each year. Together, we’re helping to close the gaps in research, education and care that children and youth with disabilities face in virtually every area of their lives.”

Last year Capes for Kids raised over $1 million and the funds raised this year, part of the hospital’s historic Together We Dare $100 million campaign, will help support research and critical hospital programs and services that include, but are not limited to:

• Building health-care system capacity: Training the next generation of health-care providers, including developmental pediatricians, to become outstanding clinicians, advocates, innovators and teachers in childhood disability who will fill urgent gaps in care and reduce wait times.
• Increasing access to orthotics and prosthetics: With digital technology including 3D-scanning and printing, the hospital’s researchers and technicians are leading a once-in-a-generation transformation in care for kids who use prosthetic and orthotic devices. These innovations will allow Holland Bloorview to deliver data-driven precision care, faster production time and lower device costs so kids at Holland Bloorview can access the care they need to improve their independence and participation.  
• Providing support to families: The Family Support Fund provides a lifeline for families at Holland Bloorview, offering financial aid to families for necessities including medical equipment, medication, recreation and respite services.
• Moving groundbreaking innovations into clinical care: It can take 17 years for research to translate into changed care practice. Holland Bloorview is bringing innovations to clinic and bedside faster. Technologies such as brain computer interface, robotics for gait training and mobility, video gaming for therapy, social play and education and wearables for anxiety management will move into clinic faster to help more kids lead healthier lives.
• Fostering creativity: The Spiral Garden helps children’s imaginations bloom. This popular outdoor art, garden and summer camp program promotes self-expression and creativity as kids transform into artists, sculptors, gardeners, puppeteers, storytellers and theatre performers.

Willow was diagnosed with cerebral palsy when she was two years old and spent three months as an inpatient at Holland Bloorview after undergoing neurosurgery—selective dorsal rhizotomy—when she was four. From the nurses and developmental pediatric fellows to the therapeutic clowns, Willow’s entire care team adapted to her needs. Whether she was baking delicious treats in the inpatient therapeutic kitchen, swimming, or learning how to ride a bike, Willow woke up each day feeling excited for therapy.

“Before coming to Holland Bloorview, Willow had never seen any children with disabilities,” says Alisa Leroux, Willow’s mom. “The hospital didn’t just provide therapy –it gave Willow belonging, confidence and life-long friendships. We’re supporting Capes for Kids because we believe that all children and youth with disabilities and developmental differences deserve these vital opportunities to develop, grow, play and thrive.”

Anyone can register for free to participate or donate at CapesforKids.ca. You can make your own cape or earn a Capes for Kids branded cape by raising your first $100 ($50 for children and youth). When you raise $1,000 you can receive a limited-edition gold cape.

More ways to get involved:

• Join us at one of several events including a trivia night in the Distillery District.
• Sign-up your workplace and your corporate team will be partnered with an honorary kid captain to help unite your team and achieve your fundraising goal!
• Get your child’s school involved, bringing disability education and fundraising together!

Everything you need to fundraise, including downloadable graphics and virtual meeting backgrounds, can be found in our Fundraising Toolkit. 

Capes for Kids is made possible through the generous support of donors, including Presenting Sponsor BMO and other supporting sponsors: TD, RBC, National Bank, Element Fleet Management, Morgan Stanley, CI Financial, Aon, Avison Young, ALLIED, Gluckstein Lawyers, Motion, Osler Hoskin & Harcourt LLP, Sodexo Canada, Roots Canada, CIBC, Schultz Law Group LLP, Ripley’s Aquarium of Canada, and in-kind sponsor, Air Canada. Special thanks to media supporters, Adapt Media, The Globe and Mail, Pattison Outdoor, Rogers Media, SJC Media, Toronto Star, Boom 97.3 and Indie 88 and Indie FM.

-30-

About Holland Bloorview Kids Rehabilitation Hospital

At Holland Bloorview we believe in creating a world where all youth and children belong. As Canada’s hospital for children with disabilities, we combine world-class care, transformational research and academic leadership in pediatric disability. Every year we help over 9,500 kids and youth with disabilities and complex medical needs access care that focuses on their physical, mental and emotional well-being, and we power their infinite potential and possibility. Together we dream big. Together we dare to shape the future of disability health care for kids. For more information or to donate, please visit hollandbloorview.ca or connect on X, Facebook, Instagram, LinkedIn and parent-blog BLOOM.

CONTACT: Ashley Cruz
Holland Bloorview Kids Rehabilitation Hospital
647-400-4351
acruz@hollandbloorview.ca

Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference




Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference

CORAL GABLES, Fla., March 06, 2026 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company will showcase real‑world findings in Duchenne muscular dystrophy (DMD) through multiple poster presentations at the 2026 MDA Clinical & Scientific Conference in Orlando, Florida. Catalyst will also sponsor a vamorolone-focused MDA Industry Forum with Santhera Pharmaceuticals.

“The MDA meeting is a key opportunity to highlight the expanding real‑world evidence shaping care for the Duchenne community,” said Will Andrews, MD, Chief Medical Officer of Catalyst. “Through our poster presentations and our sponsored symposium on long‑term evidence generation, we’re contributing clinical insights that help clarify AGAMREE^®’s profile and its role in patient care. Our commitment is to advance rigorous, meaningful research that moves the field forward for patients and their families.”

The poster presentations will focus on real-world analysis of vamorolone in patients living with DMD:

Poster Presentations:

Abstract Title: Real-world analysis of concomitant cardiac medication use with the novel corticosteroid vamorolone in patients with Duchenne muscular dystrophy (DMD)
Authors: Linda Cripe, MD, Nationwide Children’s Hospital, Steven Woods, PharmD, Catalyst, Katherine Habkouk, PharmD, AnovoRx Specialty Pharmacy, Regina Grebla, PhD, Northeast Epi, LLC
Session Name: Poster Session
Topic: Clinical Management
Poster Number: 74 S
Date of Presentation: Sunday, March 8, 2026, 6:00 PM–8:00 PM ET

Abstract Title: Association Between Glucocorticoid Treatment Duration and Health Care Resource Utilization in Duchenne Muscular Dystrophy: A Real-World Analysis.
Authors: Steven Woods, PharmD, Catalyst Pharmaceuticals, Bridget McGowan, MD, Ann and Robert H. Lurie Children’s Hospital of Chicago, Ashley Martin, PhD, BluePath Solutions, Alexa Gordon, MS, BluePath Solutions, Sana Mirza, MPH, BluePath Solutions, Paula Alvarez, MBA, MS, Rph, Critical Intelligence Consulting

Session Name: Poster Session
Topic: Other
Poster Number: 75 S
Date of Presentation: Sunday, March 8, 2026, 6:00 PM–8:00 PM ET

Abstract Title: Glucocorticoid Use and Delayed Respiratory Decline in Duchenne Muscular Dystrophy Patients: A Real-World Analysis
Authors: Steven Woods, PharmD, Catalyst Pharmaceuticals, Bridget McGowan, MD, Ann and Robert H. Lurie Children’s Hospital of Chicago, Ashley Martin, PhD, BluePath Solutions, Alexa Gordon, MS, BluePath Solutions, Sana Mirza, MPH, BluePath Solutions, Paula Alvarez, MBA, MS, Rph, Critical Intelligence Consulting, Oscar Mayer, MD, The Children’s Hospital of Philadelphia
Session Name: Poster Session
Topic: Other
Poster Number: 76S
Date of Presentation: Sunday, March 8, 2026, 6:00 PM–8:00 PM ET

MDA Industry Forum will highlight the latest insights from clinical leaders advancing our understanding of DMD:

Symposium:

Title: MDA Industry Forum Sponsored by Catalyst Pharmaceuticals in Conjunction With Santhera Pharmaceuticals
Speakers:

• Dr. Craig McDonald, MD, Chair, Department of Physical Medicine & Rehabilitation Professor, Departments of Pediatrics and Physical Medicine & Rehabilitation UC Davis Health, Sacramento, CA
• Dr. Leanne Ward, MD, Professor of Pediatrics, University of Ottawa, Ottawa, ON

Date of Presentation: Tuesday, March 10, 2026, 12:00 PM-1:30 PM ET
Location: Key Largo Room, The Hilton Orlando

About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., has been recognized by Forbes as one of America’s Most Successful Company in 2023, 2024, and 2025, and on the 2025 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.

For more information, please visit Catalyst’s website at www.catalystpharma.com.

Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst’s actual results in future periods to differ materially from forecasted results. A number of factors described in Catalyst’s Annual Report on Form 10-K for the 2025 fiscal year and its subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst’s filings with the SEC are available from the SEC, may be found on Catalyst’s website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Contact Information:

Investor Contact
Melissa Kendis, Catalyst Pharmaceuticals, Inc.
(305) 420-3200
IR@catalystpharma.com

Media Contact
Ignacio Guerrero-Ros, Ph.D., Russo Partners, LLC
(646) 249-6817
Ignacio.Guerrero-Ros@russopartnersllc.com

Catheter Precision’s LockeT Suture Retention Device to be Featured in Live Cases at ISLAA 2026




Catheter Precision’s LockeT Suture Retention Device to be Featured in Live Cases at ISLAA 2026

FORT MILL, S.C., March 06, 2026 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (NYSE American: VTAK), a pioneer in medical technology for the cardiac electrophysiology market, today announced that its LockeT suture retention device will be highlighted during live procedural cases at the International Symposium of Left Atrial Appendage 2026 conference. The event, co-hosted by the Academy for Continued Healthcare Learning (ACHL) and ISLAA Foundation, will take place from March 5-6, 2026, at the Biltmore Hotel in Los Angeles, California.

The ISLAA meeting is a multi-specialty cardiovascular educational symposium on the frontier science of left atrial appendage (LAA). Over two days, course directors and leading physicians from The Kansas City Heart Rhythm Institute, Texas Cardiac Arrhythmia Institute, Los Robles Medical Center, Mayo Clinic and Mt. Sinai will manage the program and content.

In addition, the ISLAA meeting provides a unique opportunity for hands-on demonstrations and product education for electrophysiology fellows. Catheter Precision will be participating in these sessions to provide fellows an opportunity to try LockeT, ask questions and learn more about the products benefits, which include cost reduction for the hospital and same day hospital discharge.

“We are proud that LockeT continues to gain traction at the industry’s most prestigious gatherings,” said David Jenkins, CEO of Catheter Precision. “Our recent feature at the Structural Heart Intervention and Imaging: A Practical Approach 2026 conference underscores the importance of live clinical cases. They offer an unmatched opportunity for physicians to validate the efficiency and cost-effectiveness of our suture retention solutions in a real-world setting.”

About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.

About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words.  These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.

The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

CONTACTS:

Investor Relations
973-691-2000
IR@catheterprecision.com

# # #

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization




Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

• Extends Company Cash Runway into Mid-2028
• Financing Expected to Fund Completion of Phase 2 Ovarian Cancer Trial
• Financing Supports Acceleration Toward Pivotal Trial and Commercialization
  
• Financing Structured as Non-Convertible Debt Financing

TARPON SPRINGS, Fla., March 6, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that it has closed a $20 million non-convertible debt financing with Streeterville Capital.

The transaction is structured as a note purchase agreement pursuant to which the Company issued two non-convertible promissory notes: (i) a promissory note in the original principal amount of $10,930,000 and (ii) a secured promissory note in the original principal amount of $10,000,000, together providing approximately $20 million in net proceeds to the Company.

The financing is expected to extend the Company’s cash runway into the summer of 2028. The Company intends to use the proceeds primarily to support key initiatives designed to accelerate the advance of stenoparib toward pivotal development, FDA approval and commercialization.

Additional information regarding the transaction is included in the Company’s Form 8-K filed with the Securities and Exchange Commission on March 6, 2026.

“This financing demonstrates the confidence which Streeterville has in Allarity and the capital received positions us to complete Phase 2 enrollment, prepare for our FDA meeting, advance our companion diagnostic strategy, and prepare for pivotal development of stenoparib in advanced ovarian cancer,” said Thomas Jensen, Chief Executive Officer of Allarity Therapeutics. “The financing also supports broader strategic initiatives, including further advancement of our DRP companion diagnostic platform and potential exploratory development in additional WNT-driven tumor types. We view stenoparib as a novel, highly differentiated therapeutic candidate, and this non-convertible financing provides the resources necessary to propel its continued advancement, while reflecting confidence in the strength of our clinical progress and regulatory strategy.”

Stenoparib has demonstrated durable clinical benefit in heavily pre-treated ovarian cancer patients, including previously reported extended overall survival. Notably, certain patients have remained on therapy for more than 30 months, highlighting the long-term therapeutic potential of stenoparib in this population. The open-label Phase 2 trial will generate the critical clinical data to inform future regulatory engagement and pivotal trial development.

About Stenoparib/2X-121
Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking WNT pathway activation, stenoparib’s unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer, Small Cell Lung Cancer and colorectal cancer. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121. Allarity has two ongoing Phase 2 trial protocols for stenoparib in Ovarian Cancer patients. In the first, patients who had had 2+ lines of therapy were enrolled on stenoparib and given drug twice daily. This protocol has been closed to further enrollment but continues for the enrolled patients who are still receiving benefit from stenoparib administration. The updated data from this study were presented at this AACR special conference on advances in Ovarian Cancer. Note that, as these data are from an ongoing trial, analyses may change as the study fully matures. An amended protocol designed expressly to capitalize on the emerging clinical experience with stenoparib in platinum resistant patients began enrolling patients this summer. This amended protocol enrolls only platinum resistant or platinum-ineligible patients and is designed to accelerate the clinical development of stenoparib toward FDA approval.

About the Drug Response Predictor – DRP^® Companion Diagnostic
Allarity uses its drug-specific DRP^® to select those patients who, by the gene expression signature of their cancer, may have a high likelihood of benefiting from a specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may be enhanced. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression profiles from patient biopsies. The DRP^® platform has shown an ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients across dozens of clinical studies (both retrospective and prospective). The DRP platform, which may be useful in all cancer types and is patented for dozens of anti-cancer drugs, has been extensively published in the peer-reviewed literature.

About Allarity Therapeutics
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP^® technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit www.allarity.com.

Follow Allarity on Social Media
LinkedIn: https://www.linkedin.com/company/allaritytx/

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company’s current expectations or forecasts of future events. The words “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the continued clinical development of stenoparib (2X-121) in advanced ovarian cancer and small cell lung cancer; the completion of Phase 2 enrollment; anticipated timing of critical clinical data; preparation for and timing of End-of-Phase-2 FDA meeting; potential initiation of pivotal development; the development and potential prospective use of the Company’s DRP® companion diagnostic platform; and potential exploratory development of stenoparib in additional oncology indications, including other WNT-driven tumor types; the anticipated use of proceeds from the debt financing; and the filing of a Current Report on Form 8-K. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to clinical development and regulatory review, including the possibility that future clinical data, may not support safety, efficacy, or durability claims; risks that Phase 2 enrollment may not be completed as planned; delays in patient enrollment or trial completion; risks associated with preparation for or outcome of End-of-Phase-2 FDA meeting; uncertainties regarding potential initiation or timing of pivotal development; reliance on third-party investigators, clinical sites, and manufacturing partners; the predictive accuracy, regulatory acceptance, and clinical utility of the DRP® platform; risks related to exploratory development in additional tumor types; and the Company’s ability to secure sufficient funding or strategic partnerships to support its operations and development plans; risks relating to the Company’s ability to deploy the proceeds as anticipated; satisfy its obligations under the debt instruments; complete and timely file the Form 8-K. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our Form 10-K annual report filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2025, and our Form 10-Q quarterly reports filed with the SEC on May 9, 2025, August 15, 2025 and November 14, 2025, available at the SEC’s website at www.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.

###

Company Contact:         
        investorrelations@allarity.com

        
Media Contact:
        Thomas Pedersen
        Carrotize PR & Communications
        +45 6062 9390
        tsp@carrotize.com

Attachment

• Allarity Therapeutics Press Release – Allarity Closes USD20 Million Financing

Intended Retirement of Independent Non-executive Director and changes of composition of board committees




Intended Retirement of Independent Non-executive Director and changes of composition of board committees

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 06, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Professor Mok Shu Kam, Tony has informed the Company that he would not seek re-election after retiring from the Board at the forthcoming annual general meeting of the Company to be held on May 12, 2026 (“AGM”). Professor Mok has served as an Independent Non-executive Director of the Company for more than eight years, approaching the nine-year cap on the tenure of independent non-executive directors under the Hong Kong Listing Rules. Consequently, he will cease to be an Independent Non-executive Director of the Company at the conclusion of the AGM. Upon his retirement, he will also step down from his roles as chairman and member of the board committees of the Company. 

In connection with the intended retirement of Professor Mok from the Board, the Board has approved the following changes to the composition of the board committees and the Senior and Lead Independent Non-executive Director of the Company, effective from the conclusion of the AGM, subject to the respective Directors being re-elected as Directors by the shareholders at the AGM:

(1)           Dr Renu Bhatia will be appointed as the Senior and Lead Independent Non-executive Director, and appointed on the Nomination Committee as the chairman;
(2)           Dr Chaohong Hu will be appointed as the chairman of the Technical Committee; and
(3)           Professor Tan Shao Weng, Daniel will be appointed as a member of the Sustainability Committee.

Each of Dr Bhatia, Dr Hu and Professor Tan is currently an Independent Non-executive Director of the Company.

Dr Dan Eldar, the Chairman of HUTCHMED, said: “Professor Mok has served with distinction as an Independent Non-executive Director and as chairman of both the Nomination Committee and the Technical Committee. His leadership has been instrumental in strengthening the Board composition, and guiding the scientific and clinical development programs. His internationally recognized expertise in oncology has brought invaluable perspective to the long term strategy of the Company. The Board sincerely thanks Professor Mok for his significant contributions to the growth of the Company, and we wish him all the best in his future endeavours.”

Pursuant to the requirements of Rule 13.51(2) of the Hong Kong Listing Rules, Professor Mok has confirmed that he has no disagreement with the Board and that there are no other matters that need to be brought to the attention of the shareholders of the Company in connection with his retirement from the Board.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, the risk that current or future appointees to HUTCHMED’s board of directors are not effective in their respective positions, the difficulty in locating and recruiting suitable candidates for its board of directors and the management difficulties which may arise from changes in HUTCHMED’s board of directors. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, on AІM and with The Stock Exchange of Hong Kong Limited. HUTCHMED undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.

CONTACTS

Claritas iPET™ Approved by Australia TGA to Supply the Medical Software Device for Image Processing Enabling Diagnostic Quality Images from Short Scan Time and/or Low Dose PET, PET-CT/MRI Scans




Claritas iPET™ Approved by Australia TGA to Supply the Medical Software Device for Image Processing Enabling Diagnostic Quality Images from Short Scan Time and/or Low Dose PET, PET-CT/MRI Scans

LONDON and SYDNEY, March 06, 2026 (GLOBE NEWSWIRE) — Claritas NucMed Technologies Ltd (Claritas), a healthcare technology company specializing in state-of-the-art image enhancement, noise reduction, segmentation and quantification, and related AI technologies, is pleased to announce that the Australian regulatory agency for medicines and medical devices, namely, the Therapeutic Goods Administration (TGA) has approved the software device, Claritas iPET™ for supply in Australia.

This clearance from TGA in Australia further expands the reach and use of Claritas iPET™, already cleared and used in several jurisdictions. This software tool which is agnostic to equipment type and manufacturer, and which integrates into existing hospital systems, is being used to enhance noisy and unclear Positron Emission Tomography (PET) scans for improved visibility and sharpness. The methods implemented in Claritas iPET™ ensures fine lesions are not lost on enhancement, SUV values are maintained, and no artifacts are introduced.

Hospitals and clinics use the Claritas iPET™ capabilities to process PET scans obtained with reduced scan time and/or reduced isotope dosage to yield diagnostic quality scans. Thus, increasing scan throughput and providing a much-improved patient experience, by reducing radiation exposure and scan time. Claritas iPET™ has features that enables the use of CT or MRI data to be used as an overlay to PET data for additional information and clarity.

Claritas iPET™ is being used to improve image quality to enable reducing scan time or isotope dose or a combination of the time and dosage. Dr Fernando Salis, a practicing nuclear medicine physician and director of Claritas NucMed Brazil, commented, “We are extremely pleased to see the response and demand in Brazil where hospitals have implemented Claritas iPET™ to improve the quality and efficiency of PET scans increasing the number of patients scanned per day, improving patient access and reducing cost.”

About

Claritas NucMed Technologies Ltd, a subsidiary of Claritas HealthTech Ltd, is based in London, United Kingdom, and is the authorised distributor of Claritas iPET™, iPETcertum™, iSPECTcardiac™, and other nuclear medicine devices globally.

Claritas HealthTech Ltd conducts research and development in the fields of image enhancement, machine vision and artificial intelligence (“AI”) with a focus on medical image processing and AI assisted interpretation and diagnostics. Claritas aims to transform the diagnostics industry with powerful and effective software products created using image enhancement and AI technology enabling and assisting doctors and physicians to make accurate diagnosis and improve patient lives. All Claritas products are compliant with HIPPA, DPDPA and GDPR requirements.

For more information, please visit www.claritashealthtech.com

For Enquiries, please contact:

Devika Dutt, COO

Claritas HealthTech Ltd

d.d@claritasco.com

Fagron publishes its Annual Report 2025




Fagron publishes its Annual Report 2025

Regulated information
Nazareth (Belgium)/Rotterdam (The Netherlands), 6 March 2026 7AM CET

Fagron publishes its Annual Report 2025

Fagron, the leading global player in pharmaceutical compounding, today publishes its Annual Report 2025, further to its earlier announcement of Fagron’s annual financial results for the financial year 2025 on February 12, 2026.

The Annual Report is available on Fagron’s website in both Dutch (official version, including the ESEF-tagged version) and English. It comprises the annual financial report relating to the consolidated financial statements, as well as the sustainability report, for the financial year 2025. 

The Annual Report will be presented to the Annual General Meeting of Shareholders, scheduled to be held on May 11, 2026.

Financial calendar
9 April 2026                         Trading update first quarter 2026
11 May 2026                        Annual General Meeting 2026
30 July 2026                        Half year results 2026
8 October 2026                    Trading update third quarter 2026

Results and trading updates are published at 7.00 AM CET.

Further information
Ignacio Artola
Global Head of Investor Relations
Tel. +34 670385795
ignacio.artola@fagron.com

About Fagron
Fagron is the leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 38 countries around the world.

The Belgian company Fagron NV is based in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed through the Dutch company Fagron BV with head office located in Rotterdam.

Important information regarding forward-looking statements
Certain statements in this press release may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Consequently, Fagron cannot provide any guarantee that such forward-looking statements will, in fact, materialize and cannot accept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Attachment

• 2025 Annual Report – PR